Denali Capital Acquisition Corp.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lei Huang
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 437 Madison Avenue New York City NY United States of America 10022
- IPO Date
- Jun 7, 2022
- CIK
- 0001913577
- Similar Companies
- Business
- Denali Capital Acquisition Corp. (NASDAQ: DECA) is a blank check company, or special purpose acquisition company, incorporated in 2022 as a Cayman Islands exempted company whose principal business activity focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses; it conducts no significant operations prior to completing such a transaction and holds the net proceeds of its initial public offering and private placement units in a trust account available for such purposes. Headquartered at 437 Madison Avenue, 27th Floor, New York, New York, the company offers investors exposure to potential high-impact capital market transactions by providing private companies an alternative path to public markets via its flexible structure, which includes plans for potential redomestication to Delaware post-merger; it maintains no traditional products or services beyond its SPAC vehicle, instead leveraging IPO-raised capital of approximately $51 million in private placement units and founder shares to pursue de-SPAC opportunities across various industries without predefined sector restrictions. Recent major developments include the August 30, 2024, signing of a definitive business combination agreement with Semnur Pharmaceuticals Inc., a majority-owned subsidiary of Scilex Holding Company (NASDAQ: SCLX), valuing Semnur at a pre-transaction equity of $2.5 billion, under which Denali would merge with a wholly-owned subsidiary of Semnur, domesticate to Delaware, and rename to Semnur Pharmaceuticals Inc., with registration planned for up to 292.5 million new common shares, 6 million Series A preferred shares, and 8.76 million warrants; additionally, Scilex purchased 500,000 Class B ordinary shares from Denali's sponsor via a sponsor interest purchase agreement, while the company secured multiple monthly trust account extensions through June 2025 funded by up to $180,000 in interest-free convertible promissory notes from Scilex, pushing the latest business combination deadline to December 11, 2025, amid ongoing SEC Form S-4 filings and shareholder approvals to facilitate the proposed Semnur transaction.
Florida DECA Partners with Kaplan to Expand College and Career Readiness for Students Statewide
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. Announces Adjournment of Extraordinary General Meeting of Shareholders to April 11, 2025 at 10:00 AM ET.
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
Correction: Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination